Ivaldi Diego, Burgos Mariana, Oltra Gisela, Liquitay Camila E, Garegnani Luis
Research Department Instituto Universitario Hospital Italiano de Buenos Aires Buenos Aires Argentina.
Cochrane Evid Synth Methods. 2024 May 23;2(5):e12074. doi: 10.1002/cesm.12074. eCollection 2024 May.
The preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement was developed to improve the reporting of systematic reviews (SRs) and meta-analyses. Due to the suboptimal reporting of the 2009 version, an update was performed and published in 2021. Despite having been evaluated in studies published before its publication, its adherence in SRs of interventions published after 2021 remains unclear.
To assess PRISMA 2020 statement adherence and its uptake in SRs of interventions.
We conducted a prospective cross-sectional study searching MEDLINE (PubMed), including a 10% random sample of all SRs involving human interventions published since January 2022 retrieved by our search process. We did not apply any restrictions. We assessed PRISMA 2020 statement uptake and its adherence using its expanded checklist.
We included 222 out of 945 studies. 67 (30.18%) used PRISMA 2020 statement. None adhered completely, with an average adherence of 42.64% (Min-Max: 14.29%-76.19%). Results and Methods sections had low adherence, with 40.57% (Min-Max: 10.45%-98.51%) and 25.55% (Min-Max: 7.46%-55.22%) respectively. The items with the least adherence were: certainty and reporting bias assessment, excluded studies characteristics and search strategy with 7.46% (5/67), 8.96% (6/67), 10.45% (7/67), and 11.94% (8/67) respectively.
As in previous studies, our study showed low adherence, mainly to the methods and results sections. However, our study showed a lower adherence, probably due to the use of the expanded checklist to assessed the tools adherence.
We found a low adherence rate to the PRISMA 2020 expanded checklist. Further PRISMA dissemination and targeted audience training are needed to improve SR reporting and quality.
系统评价和Meta分析的首选报告项目(PRISMA)声明旨在改善系统评价(SR)和Meta分析的报告。由于2009年版本的报告不够理想,因此进行了更新并于2021年发布。尽管在其发布之前的研究中已对其进行了评估,但其在2021年之后发表的干预措施SR中的遵循情况仍不清楚。
评估PRISMA 2020声明的遵循情况及其在干预措施SR中的应用。
我们进行了一项前瞻性横断面研究,检索MEDLINE(PubMed),包括通过我们的检索过程检索到的自2022年1月以来发表的所有涉及人类干预措施的SR的10%随机样本。我们没有施加任何限制。我们使用其扩展清单评估PRISMA 2020声明的应用及其遵循情况。
我们从945项研究中纳入了222项。67项(30.18%)使用了PRISMA 2020声明。没有一项完全遵循,平均遵循率为42.64%(最小值-最大值:14.29%-76.19%)。结果和方法部分的遵循率较低,分别为40.57%(最小值-最大值:10.45%-98.51%)和25.55%(最小值-最大值:7.46%-55.22%)。遵循率最低的项目是:确定性和报告偏倚评估、排除研究的特征和检索策略,分别为7.46%(5/67)、8.96%(6/67)、10.45%(7/67)和11.94%(8/67)。
与之前的研究一样,我们的研究显示遵循率较低,主要是在方法和结果部分。然而,我们的研究显示遵循率更低,可能是由于使用扩展清单来评估工具的遵循情况。
我们发现对PRISMA 2020扩展清单的遵循率较低。需要进一步传播PRISMA并对目标受众进行培训,以改善SR的报告和质量。